About

Bert-Arjan Millenaar, CEO and founder of NLC, went through this first-hand. His experience proves why NLC is an essential company that significantly impacts society every day.

In May 2014, Bert-Arjan became the proud father of a little girl. Unfortunately, she was born prematurely, leaving him helpless next to her incubator. He desperately wanted nothing more than to hold his little girl and bring her home. At the time, Bert-Arjan didn’t know that a professor across the country was working on an invention that could have prevented his pain. A lack of entrepreneurship and network kept the professors’ innovation (Concord Neonatal) out of our healthcare system. Unfortunately, this is just one of many stories with the same plot: a patient is in critical need of equipment that has not yet been brought to the market.

We at NLC have made it our mission to change this.

We find inventions, select the most promising ones, and build them into viable healthtech ventures to advance health.

Since 2015, NLC has evaluated thousands of inventions and built over 100 ventures. We have a great team of dedicated employees and industry experts (+3000 individuals) who enable us to continue our mission daily. We guarantee that you are in safe, trustworthy hands!

Together we are building ventures and advancing health for patients worldwide. In addition, we are an experienced fund manager that makes healthcare innovation investible for retail and institutional investors.

HOW DO WE ACHIEVE SUCCESS? THROUGH ENTREPRENEURSHIP AT SCALE!

We strongly believe that the most successful way to bring more healthtech inventions to patients is by using entrepreneurship at scale. Entrepreneurship is essential to get a venture through the early stages, and this is where you need to put in the hard work on many levels simultaneously. The dedication of the CEOs and their team is crucial to getting the venture to the market successfully.

By building ventures at scale, we can benefit from the data and learnings we’ve harvested along the way. We know the pitfalls. We know the shortcuts. We try hard, and if we fail, we fail fast. To support a venture, we build teams around it that know what it takes to make a venture successful. We surround our CEOs with expertise and support in all areas, from helping to secure finance, providing advice on patents and certifications, training the team on sales, and everything in between.

OUR NETWORK

Our network is essential to us and plays a crucial role in our journey to success. Committed specialists worldwide support our team through our venture-building process.

We partner with 4 groups of people, and together we strive for success!

  1. Inventors and research institutes that want to bring their inventions to the market with us,
  2. Medical, technical and business specialists that help us evaluate the inventions,
  3. Investors that are willing to take the risk and invest in early seed start-ups,
  4. Entrepreneurs and advisors that help us grow the ventures we have built.

Together, we overcome fragmentation so we can build ventures and advance health.

HOW DO WE HELP YOU LOWER YOUR RISK CURVE?

NLC operates at the beginning of the risk curve, where the risk is high, and the invested capital is relatively low. This opens the opportunity for us to make an impact by utilising our entrepreneurship at scale to lower the risk curve of our ventures. Our ventures are de-risked at a faster rate with low(er) costs, which scales NLC’s portfolio further (statistically) and de-risks our model.

This means fewer risks and more rewards!

Similar companies

BR

BrightEdge

BrightEdge propels groundbreaking patient-centric solutions by investing in and supporting the most innovative startup companies to advance science, reduce disparities, and promote healthcare sustainability. BrightEdge is the innovation, impact investment, and venture capital arm of the American Cancer Society (ACS). Through our donor-funded ACS Impact Venture Fund (AIVF), we further ACS’s mission by investing in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate our vision of ending cancer as we know it, for everyone. About BrightEdge and The American Cancer Society BrightEdge is helping create a stream of alternate income to sustain the critical work being done across our pillars. Donations to BrightEdge become a sustainable source of financial support to the American Cancer Society, diversifying and modernizing the ACS’s income sources. Investment returns from the AIVF portfolio are both reinvested in AIVF to further support new and existing companies in the portfolio and additional proceeds are used to sustain ACS’s lifesaving programs in research, access, and health equity. BrightEdge investment decisions and innovation programming are guided by the mission priorities of ACS and seek to achieve mission-driven social impact through its proprietary Cancer Impact Investment FrameworkTM (CIIFTM). BrightEdge builds on the American Cancer Society’s commitment to funding and conducting cancer research and plays a key role in accelerating today’s most promising oncology-focused technologies. Our ability to translate scientific discoveries into accessible cures and solutions depends on investments in entrepreneurial for-profit companies that can validate, develop, and commercialize products and services at scale in the healthcare marketplace for people facing cancer. BrightEdge plays a unique role alongside traditional venture capital firms by addressing early-stage funding gaps, incubating high-impact companies, bringing system-level knowledge to companies at critical points in product development, and helping emerging companies access world-class intellectual and human capital as they grow. Learn how BrightEdge will help improve 1.5 million lives by investing in cancer-focused therapies and technologies in its most recent annual report and infographic.

EM

EMCIFund

Address the critical bottlenecks in both established and emerging markets that limit access and affordability to novel cancer solutions. Inculcate the tenets of ESG (Environmental, Social and Governance) based investing and measure the progress and impact of our portfolio using the following metrics: E: The ability to optimize differential drug and device pricing based on geography and expand access to promising products early in their lifecycle S: Ability to boost R&D productivity through operational optimization and process transformation G: Promote ethical conduct of business and collaboration while ensuring inclusion & diversity What We DoInvest in US and EU based cancer start-ups who are keen to explore emerging markets or engage in collaborative R&D. Streamline the product-market fit and ensure access to supportive infrastructure and resources. Facilitate their collaborative R&D/commercialization strategy in geographies of interest. How We Do It Accelerate the path to successful commercialization for US and EU based start-ups developing the next generation of oncology solutions by: Reducing costs through infrastructure consolidation and collaborative expertise Expanded access to capital Facilitating rapid market penetration and commercial scaling​

HB

H7 BioCapital

Headquartered in Silicon Valley, H7 BioCapital is a global venture platform that supports the transformational growth of healthcare companies through its influential venture capital financing, global accelerator program, venture club, VC class, webinars, conferences and other strategic events, and connect them with investors, scientists, physicians, corporate partners and other industrial professionals to jointly build a resource - rich healthcare innovation ecosystem. H7 BioCapital consists of three parts of organizations: H7 Accelerator, H7 Venture, and H7 Café to support the transformational growth of healthcare by striving to be transformational itself. Need a boost with your healthcare startup? Let H7 be your support - Health, Heal, Happiness, Hope, Humanity, Home and Holistic! H7 Accelerator 3-month-long cohort-based healthcare accelerator program providing mentorship, funding and other support to early-stage biotech, medtech and device startups along with a lifelong network for these leaders and innovators. H7 Venture Investment platform providing early stage funding support to healthcare startups that are believed to have a long-term growth potential. H7 Café A high-quality startup community that supports the growth of healthcare entrepreneurs by frequent events such as networking, educational workshop, private deal flow meetings and other programs to connect the corporate, scientists, investor and founder ecosystem.

RV

RightHill Ventures

Backed by a grant from the U.S. Economic Development Administration, RightHill Ventures works in partnership with Brown, the University of Rhode Island, and other higher education institutions and their alumni to identify and fund the innovators who are developing solutions to some of the world's most challenging problems. Established by the Slater Technology Fund, a regional seed investor with deep roots in the Brown ecosystem, RightHill Ventures recruits key players from the national pool of industry and entrepreneurial talent – individuals from the broadest community – to prove our potential, build teams, and help us fuel them through early milestones. We believe that the power of university research, coupled with RightHill’s tight focus and the strength of the larger community, will result in bold launches powered by individualized investment syndicates. Leveraging Our Network of Partners Our deep ties to Brown and URI's scientific, engineering, and clinical faculty, as well as to all elements of their-and the region's-entrepreneurial ecosystem, allow us to identify the most promising innovations and connect them with the right resources to help them grow into successful companies.

KV

KHP Ventures

We’re a small team of investors, entrepreneurs, operators, clinicians, scientists and technologists, supported by our Board of healthcare and life sciences leaders and an Investment Committee of experienced venture investors and innovators. Together the partners represent one of the largest teaching hospital systems in the UK and Europe, serving a diverse local population. Their vision is to support world-leading healthcare ecosystem that drives new frontiers in modern medicine with synergistic integration of healthcare, academia, innovation and private capital.

IB

InnoCom Bio Equities

InnoCom makes investments into worthy Life Science companies, providing: Investment opportunities in cutting edge technologies Access to early commercialization for life Science innovators Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing Industry networking to access revenue at 2-3 years following pre-clinical trials Providing revenue and/or takeout at 7 years end of clinical trials Business Counsel and advice to the company management team Corporate Officer participation, setting up strong Systems, Procedures, and Protocols Board of Directors Membership, building strong Corporate Governance Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years Enhancing the delivery of health solutions to the patients who need them